Acetylsalicylic acid

Section: 29. Medicines for diseases of joints > 29.3. Medicines for juvenile joint diseases

EMLc | ATC codes: N02BA01

Indication	Mucocutaneous lymph node syndrome ICD11 code: 4A44.5
Medicine type	Chemical agent
List type	Complementary
Additional notes	Acute or chronic use for rheumatic fever, juvenile arthritis , Kawasaki disease
Formulations	**Local > Rectal > Suppository:** 150 mg ; 300 mg **Oral > Solid > dispersible tablet:** 75 mg ; 300 mg ; 500 mg **Oral > Solid > tablet:** 75 to 500 mg
EML status history	First added in 2007 (TRS 950) Changed in 2013 (TRS 985) Changed in 2025 (TRS 1064)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Wikipedia	Acetylsalicylic acid
DrugBank	Acetylsalicylic acid

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations of essential medicines for children, the Expert Committee recommended the following changes to the listing of acetylsalicylic acid: - the lower strength of the range of strengths for acetylsalicylic acid tablets be changed from 100 mg to 75 mg; - removal of the 50 mg strength of suppositories, and addition of 300 mg strength of suppositories; - addition of dispersible tablets (75 g, 300 mg and 500 mg) to facilitate dosing in children unable to swallow solid tablets.